LAMEA Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026
The Latin America, Middle East and Africa Osteoporosis Drugs Market would witness market growth of 5.3% CAGR during the forecast period (2020-2026).
Vitamin D deficiency is prevalent in the Middle East and Africa regions, despite the abundance of sunshine during the day. The rate of death after osteoporotic fracture in the area is 2-3 times that of Western societies. The main reason for this is a lack of utilities, with less than one DXA scan for 1 million people in Morocco. Among postmenopausal women, 53.9 percent had osteopenia and 28.4 had osteoporosis. Hip fractures have risen from 1008 a year in 2008 to four times the initial level in 2050.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
Vitamin D deficiency is prevalent in the Middle East and Africa regions, despite the abundance of sunshine during the day. The rate of death after osteoporotic fracture in the area is 2-3 times that of Western societies. The main reason for this is a lack of utilities, with less than one DXA scan for 1 million people in Morocco. Among postmenopausal women, 53.9 percent had osteopenia and 28.4 had osteoporosis. Hip fractures have risen from 1008 a year in 2008 to four times the initial level in 2050.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration
- Oral
- Injectable and
- Other Route of Administration
- Bisphosphonates
- Rank Ligand Inhibitors
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors Modulator (SERM) and
- Other Drug Classes
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Allergan PLC
- Eli Lilly and Company
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Osteoporosis Drugs Market, by Route of Administration
1.4.2 LAMEA Osteoporosis Drugs Market, by Drug Class
1.4.3 LAMEA Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION
3.1 LAMEA Oral Market by Country
3.2 LAMEA Injectable Market by Country
3.3 LAMEA Other Route of Administration Market by Country
CHAPTER 4. LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS
4.1 LAMEA Bisphosphonates Market by Country
4.2 LAMEA Rank Ligand Inhibitors Market by Country
4.3 LAMEA Parathyroid Hormone Therapy Market by Country
4.4 LAMEA Calcitonin Market by Country
4.5 LAMEA Other Drug Class Market by Country
CHAPTER 5. LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY
5.1 Brazil Osteoporosis Drugs Market
5.1.1 Brazil Osteoporosis Drugs Market by Route of Administration
5.1.2 Brazil Osteoporosis Drugs Market by Drug Class
5.2 Argentina Osteoporosis Drugs Market
5.2.1 Argentina Osteoporosis Drugs Market by Route of Administration
5.2.2 Argentina Osteoporosis Drugs Market by Drug Class
5.3 UAE Osteoporosis Drugs Market
5.3.1 UAE Osteoporosis Drugs Market by Route of Administration
5.3.2 UAE Osteoporosis Drugs Market by Drug Class
5.4 Saudi Arabia Osteoporosis Drugs Market
5.4.1 Saudi Arabia Osteoporosis Drugs Market by Route of Administration
5.4.2 Saudi Arabia Osteoporosis Drugs Market by Drug Class
5.5 South Africa Osteoporosis Drugs Market
5.5.1 South Africa Osteoporosis Drugs Market by Route of Administration
5.5.2 South Africa Osteoporosis Drugs Market by Drug Class
5.6 Nigeria Osteoporosis Drugs Market
5.6.1 Nigeria Osteoporosis Drugs Market by Route of Administration
5.6.2 Nigeria Osteoporosis Drugs Market by Drug Class
5.7 Rest of LAMEA Osteoporosis Drugs Market
5.7.1 Rest of LAMEA Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of LAMEA Osteoporosis Drugs Market by Drug Class
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Osteoporosis Drugs Market, by Route of Administration
1.4.2 LAMEA Osteoporosis Drugs Market, by Drug Class
1.4.3 LAMEA Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION
3.1 LAMEA Oral Market by Country
3.2 LAMEA Injectable Market by Country
3.3 LAMEA Other Route of Administration Market by Country
CHAPTER 4. LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS
4.1 LAMEA Bisphosphonates Market by Country
4.2 LAMEA Rank Ligand Inhibitors Market by Country
4.3 LAMEA Parathyroid Hormone Therapy Market by Country
4.4 LAMEA Calcitonin Market by Country
4.5 LAMEA Other Drug Class Market by Country
CHAPTER 5. LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY
5.1 Brazil Osteoporosis Drugs Market
5.1.1 Brazil Osteoporosis Drugs Market by Route of Administration
5.1.2 Brazil Osteoporosis Drugs Market by Drug Class
5.2 Argentina Osteoporosis Drugs Market
5.2.1 Argentina Osteoporosis Drugs Market by Route of Administration
5.2.2 Argentina Osteoporosis Drugs Market by Drug Class
5.3 UAE Osteoporosis Drugs Market
5.3.1 UAE Osteoporosis Drugs Market by Route of Administration
5.3.2 UAE Osteoporosis Drugs Market by Drug Class
5.4 Saudi Arabia Osteoporosis Drugs Market
5.4.1 Saudi Arabia Osteoporosis Drugs Market by Route of Administration
5.4.2 Saudi Arabia Osteoporosis Drugs Market by Drug Class
5.5 South Africa Osteoporosis Drugs Market
5.5.1 South Africa Osteoporosis Drugs Market by Route of Administration
5.5.2 South Africa Osteoporosis Drugs Market by Drug Class
5.6 Nigeria Osteoporosis Drugs Market
5.6.1 Nigeria Osteoporosis Drugs Market by Route of Administration
5.6.2 Nigeria Osteoporosis Drugs Market by Drug Class
5.7 Rest of LAMEA Osteoporosis Drugs Market
5.7.1 Rest of LAMEA Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of LAMEA Osteoporosis Drugs Market by Drug Class
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense
LIST OF TABLES
TABLE 1 LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 2 LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 3 LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 4 LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 5 LAMEA ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 LAMEA ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 LAMEA INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 LAMEA INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 12 LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 13 LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 LAMEA CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 LAMEA CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 BRAZIL OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 26 BRAZIL OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 27 BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 28 BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 29 BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 30 BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 31 ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 32 ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 33 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 34 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 35 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 36 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 37 UAE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 38 UAE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 39 UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 40 UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 41 UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 42 UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 43 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 46 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 47 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 48 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 49 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 52 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 53 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 54 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 55 NIGERIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 56 NIGERIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 57 NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 58 NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 59 NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 60 NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 61 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 64 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 65 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 66 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – AMGEN, INC.
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 70 KEY INFORMATION - MERCK & CO., INC.
TABLE 71 KEY INFORMATION – NOVARTIS AG
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 75 KEY INFORMATION – ALLERGAN PLC
TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 1 LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 2 LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 3 LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 4 LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 5 LAMEA ORAL MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 LAMEA ORAL MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 LAMEA INJECTABLE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 LAMEA INJECTABLE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 LAMEA OTHER ROUTE OF ADMINISTRATION MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 12 LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 13 LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 LAMEA BISPHOSPHONATES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 LAMEA RANK LIGAND INHIBITORS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 LAMEA PARATHYROID HORMONE THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 LAMEA CALCITONIN MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 LAMEA CALCITONIN MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 LAMEA OTHER DRUG CLASS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 24 LAMEA OSTEOPOROSIS DRUGS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 25 BRAZIL OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 26 BRAZIL OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 27 BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 28 BRAZIL OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 29 BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 30 BRAZIL OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 31 ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 32 ARGENTINA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 33 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 34 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 35 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 36 ARGENTINA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 37 UAE OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 38 UAE OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 39 UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 40 UAE OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 41 UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 42 UAE OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 43 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 44 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 45 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 46 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 47 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 48 SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 49 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 50 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 51 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 52 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 53 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 54 SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 55 NIGERIA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 56 NIGERIA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 57 NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 58 NIGERIA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 59 NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 60 NIGERIA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 61 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2016 - 2019, USD MILLION
TABLE 62 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET, 2020 - 2026, USD MILLION
TABLE 63 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2016 - 2019, USD MILLION
TABLE 64 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2020 - 2026, USD MILLION
TABLE 65 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2016 - 2019, USD MILLION
TABLE 66 REST OF LAMEA OSTEOPOROSIS DRUGS MARKET BY DRUG CLASS, 2020 - 2026, USD MILLION
TABLE 67 KEY INFORMATION – AMGEN, INC.
TABLE 68 KEY INFORMATION – F. HOFFMANN-LA ROCHE LTD.
TABLE 69 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 70 KEY INFORMATION - MERCK & CO., INC.
TABLE 71 KEY INFORMATION – NOVARTIS AG
TABLE 72 KEY INFORMATION – PFIZER, INC.
TABLE 73 KEY INFORMATION – SUN PHARMACEUTICAL INDUSTRIES LTD.
TABLE 74 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 75 KEY INFORMATION – ALLERGAN PLC
TABLE 76 KEY INFORMATION – ELI LILLY AND COMPANY
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
